Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE -- Ignore unavailable to you. Want to Upgrade?

To: swoboda4 who wrote (237)	10/28/1997 9:59:00 PM
From: Coha	Read Replies (1) \| Respond to of 670

Yes, a newsletter called 'The Patient Investor' also follows Procyte (or did as of May, I don't subscribe - they were handing them out at the shareholders meeting). The market for a long time now has priced this company at a steep discount to book and at times cash. For those of you new to the story, it got steeper as the COB methodically sold off shares in a grotesque and utterly bizarre pattern last spring. Hence "the market" now ignores the significant changes that have taken place over the last year, not the least of which is Jack Clifford and the move from development to production/sales. The good news out of the latest financials is a continued decline in costs, particularly r&d. R&d is an unfortunate victim of the current strategy but required if this company is going to make it. Sales, however, need to begin a more consistent ramp, and I hope to discuss some of these issues with their IR later this week. I'll let you know what the company line is on sequential sales and contract manufacture and maybe something on the future of some of the tech assets the company hopes to partner or unload. Coha